Skip to main content
Premium Trial:

Request an Annual Quote

Robert Monaghan Appointed CEO of Zyomyx

NEW YORK, June 10 - Protein biochip company Zyomyx has tapped Robert Monaghan as its new CEO, the company said yesterday.

 

Monaghan replaces Lawrence Cohen, who has been CEO and president of the company since 2001. Cohen has been named vice chairman, and will continue to work full time at the Hayward, Calif.-based company.

 

Most recently, Monaghan served as president of Sigma Diagnostics, as well as its subsidiaries, and supervised the sale of the company in 2002. He also has served as a vice president of R&D at Dade Behring, vice president of sales at Behring Diagnostics, and in business development, marketing, and sales positions with SYVA, a division of Syntex pharmaceuticals; Ciba Corning Diagnostics, Health Charge Corporation, hospital finance consulting group Amherst Associates, group, and the American Hospital Supply Corporation. 

 

Zyomyx's transition in leadership also reflects a change in strategy, executives said. The company is aiming to move toward of commercialization of its Protein Profiling Biochips.  

 

"Based on customer feedback, Zyomyx will be focusing on the commercialization of products to facilitate therapeutic and diagnostic programs, with emphasis in inflammation, cardiovascular, and oncology, in line with the unique capabilities of our current protein biochip line and biochip products in our pipeline," Monaghan said in a statement.

 

The Protein Profiling chips are designed, like microarrays, to enable researchers to profile expression of 30 proteins in human serum samples at once. Currently, the company has a human cytokine profiling chip.

 

Monaghan has also been appointed to Zyomyx's board of directors.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.